KR102380115B1 - Compositions containing safflower seed extract - Google Patents
Compositions containing safflower seed extract Download PDFInfo
- Publication number
- KR102380115B1 KR102380115B1 KR1020200109017A KR20200109017A KR102380115B1 KR 102380115 B1 KR102380115 B1 KR 102380115B1 KR 1020200109017 A KR1020200109017 A KR 1020200109017A KR 20200109017 A KR20200109017 A KR 20200109017A KR 102380115 B1 KR102380115 B1 KR 102380115B1
- Authority
- KR
- South Korea
- Prior art keywords
- extraction
- extract
- equation
- safflower
- ultrasonic extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 229940023866 safflower seed extract Drugs 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 74
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 67
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 67
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 111
- 238000000605 extraction Methods 0.000 claims description 82
- 229930003935 flavonoid Natural products 0.000 claims description 34
- 235000017173 flavonoids Nutrition 0.000 claims description 34
- 150000002215 flavonoids Chemical class 0.000 claims description 34
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 34
- 235000013824 polyphenols Nutrition 0.000 claims description 34
- 230000002292 Radical scavenging effect Effects 0.000 claims description 28
- 230000000903 blocking effect Effects 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 claims description 27
- 238000000540 analysis of variance Methods 0.000 claims description 24
- 230000004044 response Effects 0.000 claims description 23
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 22
- 239000002537 cosmetic Substances 0.000 claims description 21
- 201000000849 skin cancer Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 235000013376 functional food Nutrition 0.000 claims description 17
- 230000036541 health Effects 0.000 claims description 17
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 201000001441 melanoma Diseases 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 238000005457 optimization Methods 0.000 claims description 8
- 238000005211 surface analysis Methods 0.000 claims description 7
- 230000006750 UV protection Effects 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 16
- 239000000843 powder Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- -1 fraction Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000000401 methanolic extract Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 235000018553 tannin Nutrition 0.000 description 6
- 239000001648 tannin Substances 0.000 description 6
- 229920001864 tannin Polymers 0.000 description 6
- 238000002137 ultrasound extraction Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229940079894 benzophenone-9 Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QBUKAFSEUHGMMX-MTJSOVHGSA-N (5z)-5-[[3-(1-hydroxyethyl)thiophen-2-yl]methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical compound C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C=1SC=CC=1C(C)O QBUKAFSEUHGMMX-MTJSOVHGSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150068332 KIT gene Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- YAHHPOUXPBUKTL-DXKBKMAZSA-N thymidine dimer Chemical compound CC12C(C3N([C@H]4C[C@H](O)[C@@H](CO)O4)C(=O)NC(=O)C13C)N([C@H]1C[C@H](O)[C@@H](CO)O1)C(=O)NC2=O YAHHPOUXPBUKTL-DXKBKMAZSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 홍화씨 초음파 추출물을 유효성분으로 함유하는 화장료 조성물, 약학 조성물 및 건강기능식품에 관한 것이다.The present invention relates to a cosmetic composition, a pharmaceutical composition, and a health functional food containing the ultrasonic extract of safflower seed as an active ingredient.
피부는 몸의 최외각에서 장벽과 같은 역할을 하여 외부 환경으로부터 몸 안의 각종 기관과 근육 등을 보호하는 조직이다. 인간의 신체 기관 중 가장 무거운 기관으로 단열과 체온 조절 기능도 가지고 있다. 온도와 압력, 통증 등 여러 자극에 대한 감각 기관으로의 역할도 하며 지질과 수분의 저장, 비타민 D의 합성에도 관여한다. The skin acts as a barrier in the outermost part of the body, protecting various organs and muscles in the body from the external environment. As the heaviest organ in the human body, it also has thermal insulation and temperature regulation functions. It also acts as a sensory organ to various stimuli such as temperature, pressure, and pain, and is also involved in the storage of lipids and water, and the synthesis of vitamin D.
피부암이란 피부 조직에 형성되는 모든 악성 종양을 총칭하여 일컫는 용어이다. 피부암은 주로 자외선 등의 환경적인 외부 자극 또는 유전적 요인들에 의해 유발된다. KIT 유전자 등 몇 가지 유전자에서의 가족력이 피부암에 영향이 있다는 것이 알려져 있다. 하지만 무엇보다 큰 영향을 미치는 것으로 알려진 요인은 자외선과 같은 외부자극으로서, 서구식 생활 습관의 도입으로 야외 활동이 잦아진 점, 선탠 및 태닝 기구의 사용이 늘어난 점, 오존층의 약화로 투과 자외선 양이 늘어난 점 등에 의해 피부암 발생율이 점차 증가되는 추세이다. Skin cancer is a generic term for all malignant tumors formed in skin tissue. Skin cancer is mainly caused by external environmental stimuli such as ultraviolet rays or genetic factors. It is known that a family history of several genes, such as the KIT gene, influences skin cancer. However, the factors known to have the greatest influence above all are external stimuli such as ultraviolet rays, the fact that outdoor activities have increased due to the introduction of Western-style lifestyles, the use of tanning and tanning equipment has increased, and the amount of transmitted ultraviolet rays due to the weakening of the ozone layer The incidence of skin cancer is on the rise.
많은 양의 자외선에 노출되어 세포 내부의 DNA에 티미딘 이량체(thymidine dimer)가 형성되거나 이중가닥 절단(double-strand breakage)이 일어날 수 있다. 손상된 DNA가 제대로 복구되지 못하게 되면 원발암 유전자가 발암 유전자로 바뀌고, 종양억제 유전자가 제 기능을 못하게 될 수 있다. 이 경우 피부 세포 내부의 분열 조절 기전이 정상적으로 작동하지 않아 증식이 제한되지 않고 결국 정상 세포가 종양 세포로 변이된다. 암화된 조직은 호르몬 분비 등을 통해 주변부의 혈관을 끌어들여 영양분을 공급받는 동시에 암화된 세포들 자체도 림프절과 혈관을 통해 몸의 다른 곳으로 전이 되게 된다. Exposure to a large amount of UV light may cause the formation of a thymidine dimer or double-strand breakage in the DNA inside the cell. If damaged DNA cannot be repaired properly, proto-oncogenes can be turned into oncogenes, and tumor suppressor genes can become dysfunctional. In this case, the division-regulating mechanism inside the skin cells does not work normally, so proliferation is not limited, and normal cells are eventually transformed into tumor cells. Cancerous tissues are supplied with nutrients by attracting peripheral blood vessels through hormone secretion, etc., while cancerous cells themselves are metastasized to other parts of the body through lymph nodes and blood vessels.
피부에서 종양 발생을 시작한 경우를 '원발성' 피부암으로 분류하고, 다른 장기에서 종양 발생을 시작한 후 전이되어 피부에 새로이 정착한 경우는 '전이성' 피부암이라고 분류하는데, 일반적으로 사용되는 정의의 피부암은 원발성 피부암을 의미한다. 코카서스 계통의 사람들에겐 상당히 흔한 암이지만, 일반적으로는 내부 장기에 생기는 암에 비해 치사율이 낮기 때문에 아직까지 활발히 연구되지 않고 있다. A skin cancer that begins to develop in the skin is classified as a 'primary' skin cancer, and a case that metastasizes and settles in the skin after starting a tumor in another organ is classified as a 'metastatic' skin cancer. means skin cancer. Although it is a fairly common cancer among people of Caucasus descent, it has not been actively studied because the fatality rate is generally low compared to cancers occurring in internal organs.
피부암은 2012년 통계를 기준으로 국내 발병 전체 암 중 2.0%를 차지하고 있다. CT, 초음파 등의 검진기기뿐 아니라 육안이나 조직검사를 통해서도 진단할 수 있으나 징후들을 가볍게 넘기다 초기 발견이 늦는 경우가 많아 완치율과 생존율이 높지 않다. 피부암은 피부 조직을 구성하는 세포들 중 어떤 세포로부터 유래했는가에 따라 편평상피세포암, 기저세포암, 흑색종 등으로 나누어진다. 표피의 각질형성세포로부터 유래한 악성종양인 편평상피세포암과, 표피의 최하인 기저층이나 모낭의 세포가 악성종양화한 기저세포암은 우리나라에서 유병하는 피부암 중에서는 상당히 흔한 피부암이나 상대적으로 치사율이 낮다. 반면, 악성 흑색종(malignant melanoma)은 피부의 색을 결정하는 멜라닌 세포에서 유래한 암이며 악성도가 가장 높고 침윤과 전이가 잘되어 생존율이 낮은 위험한 암이다.Skin cancer accounts for 2.0% of all cancers in Korea based on 2012 statistics. Diagnosis can be made not only through examination devices such as CT and ultrasound, but also through visual or biopsy. Skin cancer is classified into squamous cell carcinoma, basal cell carcinoma, melanoma, and the like, depending on which cell among the cells constituting the skin tissue is derived. Squamous cell carcinoma, which is a malignant tumor derived from keratinocytes of the epidermis, and basal cell carcinoma, which is a malignant tumor of cells in the basal layer or hair follicle, which is the lowest layer of the epidermis, are quite common skin cancers in Korea, but have a relatively low fatality rate. low. On the other hand, malignant melanoma (malignant melanoma) is a cancer derived from melanocytes that determine the color of the skin, and is a dangerous cancer with the highest malignancy and low survival rate due to good invasion and metastasis.
블루라이트(blue light)는 가시광선 영역에서 푸른색 계열의 빛으로 높은 에너지를 갖는 380~500 nm 파장의 빛으로 한낮에 외부 활동 시 피폭량이 많아지나 최근 스마트 기기의 보급이 확산되면서 TV, 컴퓨터, 스마트폰 등의 디스플레이와 LED 조명기기에서 많이 방출되고 있다. 특히, 블루라이트가 피부 세포 속의 미토콘드리아 DNA를 손상시키고 활성산소를 생성하여 세포의 기능장애, 세포노화 및 종양 발생을 야기하며 멜라닌 생성을 유도함으로써 피부의 착색 또는 기미를 생성하는 주요 원인이 된다고 밝혀져 있다. 현재까지, 블루라이트로부터 피부를 보호하는 방법 및 조성물에 대한 개발은 아직 미흡한 상태로 화장품업계는 자외선 차단을 중심으로 피부 자극을 줄이기 위해 화학물질 대체를 위한 천연물을 사용한 다수의 제품을 개발하고 있는 실정이다.Blue light is a blue light with high energy in the visible ray region with a wavelength of 380 ~ 500 nm. It is widely emitted from displays such as smartphones and LED lighting devices. In particular, blue light damages mitochondrial DNA in skin cells and generates reactive oxygen species, causing cell dysfunction, cellular aging and tumor development, and inducing melanin production to become the main cause of skin pigmentation or blemishes. . Until now, the development of methods and compositions for protecting the skin from blue light is still insufficient, and the cosmetic industry is developing a number of products using natural substances to replace chemical substances in order to reduce skin irritation with a focus on UV protection. am.
따라서, 자외선 및 블루라이트를 차단하고 나아가 피부암을 예방, 개선 또는 치료할 수 있는 천연물질의 개발이 요구되고 있다.Accordingly, there is a demand for the development of natural substances that can block ultraviolet and blue light and further prevent, improve, or treat skin cancer.
본 발명의 목적은 홍화씨 초음파 추출물을 유효성분으로 함유하여 항산화, 자외선 차단 및 블루라이트를 차단할 수 있는 화장료 조성물을 제공하는데 있다.It is an object of the present invention to provide a cosmetic composition capable of blocking antioxidants, UV rays and blue light by containing the ultrasonic extract of safflower seeds as an active ingredient.
또한, 본 발명의 다른 목적은 홍화씨 초음파 추출물을 유효성분으로 함유하여 항산화, 자외선 차단 및 블루라이트를 차단할 수 있는 건강기능식품을 제공하는데 있다. In addition, another object of the present invention is to provide a health functional food containing safflower seed ultrasonic extract as an active ingredient, which can block antioxidants, UV rays and blue light.
또한, 본 발명의 다른 목적은 홍화씨 초음파 추출물을 유효성분으로 함유하여 피부암을 예방 또는 치료할 수 있는 약학 조성물을 제공하는데 있다.In addition, another object of the present invention is to provide a pharmaceutical composition that can prevent or treat skin cancer by containing the ultrasonic extract of safflower seeds as an active ingredient.
상기한 목적을 달성하기 위한 본 발명의 항산화, 자외선 차단 및 블루라이트 차단용 화장료 조성물은 홍화씨(Safflower Seed) 초음파 추출물을 유효성분으로 포함할 수 있다.The cosmetic composition for antioxidant, UV protection and blue light blocking of the present invention for achieving the above object may include safflower seed ultrasonic extract as an active ingredient.
상기 홍화씨 초음파 추출물은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매 하에서 추출될 수 있다.The safflower seed ultrasonic extract may be extracted under water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 혼합용매는 20 내지 99.5 부피%의 메탄올, 에탄올, 부탄올 또는 프로판올 수용액일 수 있다.The mixed solvent may be an aqueous solution of 20 to 99.5% by volume of methanol, ethanol, butanol or propanol.
상기 홍화씨 초음파 추출물은 50 내지 700 W 파워의 초음파기로 10 내지 60분 동안 처리된 것일 수 있다.The safflower seed ultrasonic extract may be processed for 10 to 60 minutes with an ultrasonicator of 50 to 700 W power.
상기 초음파 처리 시 추출온도는 20 내지 85 ℃일 수 있다.The extraction temperature during the ultrasonic treatment may be 20 to 85 ℃.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 항산화, 자외선 차단 및 블루라이트 차단용 건강기능식품은 홍화씨(Safflower Seed) 초음파 추출물을 유효성분으로 포함할 수 있다.In addition, the health functional food for antioxidant, UV protection and blue light blocking of the present invention for achieving the above other object may include safflower seed ultrasonic extract as an active ingredient.
또한, 상기한 또 다른 목적을 달성하기 위한 본 발명의 반응표면분석법을 이용하여 항산화용 홍화씨 초음파 추출물을 제조하는 방법은 (A) 홍화씨를 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매인 추출용매, 20 내지 85 ℃의 추출온도, 10 내지 60분의 추출시간 하에서 20 내지 50 kHz의 진동수 및 50 내지 700 W 파워의 초음파기로 추출한 후 원심분리하여 수득한 상등액의 총 폴리페놀에 대한 실험값을 획득하는 단계; (B) 상기 (A)단계의 실험값을 이용하여 하기 [수학식 1]로 표시되는 2차 회귀식 모델을 도출하는 단계; (C) 상기 (B)단계에서 도출된 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계; (D) 상기 (A)단계에서 수득한 상등액의 총 플라보노이드 함량에 대한 실험값을 획득하는 단계; (E) 상기 (D)단계의 실험값을 이용하여 하기 [수학식 2]로 표시되는 2차 회귀식 모델을 도출하는 단계; (F) 상기 (E)단계에서 도출된 2차 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계; (G) 상기 (A)단계에서 수득한 상등액의 DPPH 라디칼 소거능에 대한 실험값을 획득하는 단계; (H) 상기 (G)단계의 실험값을 이용하여 하기 [수학식 3]으로 표시되는 2차 회귀식 모델을 도출하는 단계; (I) 상기 (H)단계에서 도출된 2차 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계; 및 (J) 상기 (C), (F) 및 (I)단계에서 수득된 반응표면곡선을 겹치기기법(superimposing)으로 총 폴리페놀 함량, 총 플라보노이드 함량, DPPH 라디칼 소거능에 대한 공통의 최적화 조건을 예측하는 단계;를 포함할 수 있다; In addition, the method for preparing the ultrasonic extract of safflower seeds for antioxidant using the reaction surface analysis method of the present invention for achieving the above another object is (A) safflower seeds with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. Experimental values for total polyphenols in the supernatant obtained by centrifugation after extraction with an extraction solvent, an extraction temperature of 20 to 85 ° C, an extraction time of 10 to 60 minutes, a frequency of 20 to 50 kHz and an ultrasonicator of 50 to 700 W power obtaining; (B) deriving a quadratic regression model represented by the following [Equation 1] using the experimental value of step (A); (C) verifying reliability by performing analysis of variance (ANOVA) on the regression model derived in step (B), and obtaining a response surface curve for the extraction conditions; (D) obtaining an experimental value for the total flavonoid content of the supernatant obtained in step (A); (E) deriving a quadratic regression model represented by the following [Equation 2] using the experimental value of step (D); (F) verifying reliability by performing analysis of variance (ANOVA) on the quadratic regression model derived in step (E), and obtaining a response surface curve for the extraction conditions; (G) obtaining an experimental value for the DPPH radical scavenging ability of the supernatant obtained in step (A); (H) deriving a quadratic regression model represented by the following [Equation 3] using the experimental values of the step (G); (I) verifying reliability by performing analysis of variance (ANOVA) on the quadratic regression model derived in step (H), and obtaining a response surface curve for the extraction conditions; and (J) predicting common optimization conditions for total polyphenol content, total flavonoid content, and DPPH radical scavenging ability by superimposing the response surface curves obtained in steps (C), (F) and (I) may include;
[수학식 1][Equation 1]
YTPC=-4.81776-0.015551X1+0.28967X2+0.21412X3+6.72730E-005X1X2+6.01865E-004X1X3-1.00677E-003X2X3-1.23645E-004X1 2- 2.01372E-0.03X2 2-1.42821E-003X3 2 Y TPC =-4.81776-0.015551X 1 +0.28967X 2 +0.21412X 3 +6.72730E-005X 1 X 2 +6.01865E-004X 1 X 3 -1.00677E-003X 2 X 3 -1.23645E-004X 1 2 - 2.01372 E-0.03X 2 2 -1.42821E-003X 3 2
[수학식 2][Equation 2]
YTFC=-0.37372+9.55406E-003X1+9.20547E-003X2+2.05361E-003X3-9.72712E-005X1X2-5.20451E-005X1X3+5.37565E-005X2X3-1.77861E-005X1 2-4.02178E-005X2 2-1.79762E-005X3 2 Y TFC =-0.37372+9.55406E-003X 1 +9.20547E-003X 2 +2.05361E-003X 3 -9.72712E-005X 1 X 2 -5.20451E-005X 1 X 3 +5.37565E-005X 2 X 3 -1.77861E -005X 1 2 -4.02178E-005X 2 2 -1.79762E-005X 3 2
[수학식 3][Equation 3]
YDPPH=-16.21374-0.19557X1+0.64596X2+1.96052X3+5.50661E-004X1X2+2.93686E-003X1X3-3.62518E-003X2X3+4.25974E-004X1 2-2.87540E-003X2 2-0.013343X3 2 Y DPPH =-16.21374-0.19557X 1 +0.64596X 2 +1.96052X 3 +5.50661E-004X 1 X 2 +2.93686E-003X 1 X 3 -3.62518E-003X 2 X 3 +4.25974E-004X 1 2 -2.87540 E-003X 2 2 -0.013343X 3 2
상기 수학식 1 내지 3에서, YTPC는 총 폴리페놀 함량의 예측값(mg GAE/g DM), YTFC는 총 플라보노이드 함량의 예측값(mg QE/g DM), YDPPH는 DPPH 라디칼 소거능의 예측값(%), X1은 추출시간, X2는 추출온도, X3는 추출용매의 농도이다.In Equations 1 to 3, Y TPC is the predicted value of the total polyphenol content (mg GAE / g DM), Y TFC is the predicted value of the total flavonoid content (mg QE / g DM), Y DPPH is the predicted value of the DPPH radical scavenging ability ( %), X 1 is the extraction time, X 2 is the extraction temperature, and X 3 is the concentration of the extraction solvent.
상기 DPPH 라디칼 소거능, 총 폴리페놀 함량 및 총 플라보노이드 함량에 대한 공통의 최적화 조건에 따른 추출조건은 추출 시간 35.38분, 추출 온도 79.38 ℃ 및 에탄올 농도 80%일 수 있다.Extraction conditions according to common optimization conditions for the DPPH radical scavenging ability, total polyphenol content, and total flavonoid content may be an extraction time of 35.38 minutes, an extraction temperature of 79.38° C., and an ethanol concentration of 80%.
또한, 상기한 또 다른 목적을 달성하기 위한 본 발명의 피부암을 예방 또는 치료할 수 있는 약학 조성물은 홍화씨(Safflower Seed) 초음파 추출물을 유효성분으로 포함할 수 있다.In addition, the pharmaceutical composition capable of preventing or treating skin cancer of the present invention for achieving the above another object may include safflower seed ultrasonic extract as an active ingredient.
상기 피부암은 흑색종일 수 있다.The skin cancer may be melanoma.
본 발명의 홍화씨 초음파 추출물을 유효성분으로 포함하는 항산화, 자외선 차단 및 블루라이트 차단용 조성물은 항산화 효과가 우수하며, 자외선 차단 및 블루라이트 차단에 효과가 있을 뿐만 아니라 피부암을 개선, 예방 또는 치료할 수 있으므로 건강기능식품 또는 약학 조성물로 활용될 수 있다.The composition for antioxidant, UV-blocking, and blue-light blocking, comprising the ultrasonic extract of safflower seed of the present invention as an active ingredient, has excellent antioxidant effects and is effective in blocking UV and blue light as well as improving, preventing or treating skin cancer. It can be used as a health functional food or pharmaceutical composition.
도 1은 본 발명의 실시예에 따라 제조된 홍화씨 초음파 추출물을 이용 시 총 폴리페놀 함량(TPC)에 영향을 미치는 조건을 나타낸 일변수 곡선이다.
도 2는 본 발명의 실시예에 따라 제조된 홍화씨의 초음파 추출 조건에 따른 총 폴리페놀 함량(TPC)의 3차원 반응표면곡선이다.
도 3은 본 발명의 실시예에 따라 제조된 홍화씨 초음파 추출물을 이용 시 총 플라보노이드 함량(TFC)에 영향을 미치는 조건을 나타낸 일변수 곡선이다.
도 4는 본 발명의 실시예에 따라 제조된 홍화씨의 초음파 추출 조건에 따른 총 플라보노이드 함량(TFC)의 3차원 반응표면곡선이다.
도 5는 본 발명의 실시예에 따라 제조된 홍화씨 초음파 추출물을 이용 시 DPPH 라디칼 저해활성에 영향을 미치는 조건을 나타낸 일변수 곡선이다.
도 6은 본 발명의 실시예에 따라 제조된 홍화씨의 초음파 추출 조건에 따른 DPPH 라디칼 저해활성의 3차원 반응표면곡선이다.1 is a univariate curve showing the conditions affecting the total polyphenol content (TPC) when using the ultrasonic extract of safflower seed prepared according to an embodiment of the present invention.
2 is a three-dimensional response surface curve of the total polyphenol content (TPC) according to the ultrasonic extraction conditions of safflower seeds prepared according to an embodiment of the present invention.
3 is a univariate curve showing the conditions affecting the total flavonoid content (TFC) when using the ultrasonic extract of safflower seed prepared according to an embodiment of the present invention.
4 is a three-dimensional response surface curve of the total flavonoid content (TFC) according to the ultrasonic extraction conditions of safflower seeds prepared according to an embodiment of the present invention.
5 is a univariate curve showing the conditions affecting the DPPH radical inhibitory activity when using the ultrasonic extract of safflower seed prepared according to an embodiment of the present invention.
6 is a three-dimensional response surface curve of DPPH radical inhibitory activity according to ultrasonic extraction conditions of safflower seeds prepared according to an embodiment of the present invention.
본 발명은 홍화씨 초음파 추출물을 유효성분으로 함유하는 화장료 조성물, 약학 조성물 및 건강기능식품에 관한 것이다.The present invention relates to a cosmetic composition, a pharmaceutical composition, and a health functional food containing the ultrasonic extract of safflower seed as an active ingredient.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 조성물은 홍화씨 초음파 추출물을 유효성분으로 함유한다.The composition of the present invention contains safflower seed ultrasonic extract as an active ingredient.
상기 홍화씨는 혈중 콜레스테롤의 농도를 저하시키는 작용을 하여 동맥경화, 고지혈증, 고혈압 등 순환기 질환의 예방과 치료에 효과가 크며, 뼈를 튼튼하게 해 골절, 골다공증, 골형성부전증 등의 치료 효과가 있다.The safflower seed acts to lower the concentration of cholesterol in the blood, so it is effective in the prevention and treatment of circulatory diseases such as arteriosclerosis, hyperlipidemia, and high blood pressure, and it has a therapeutic effect on fractures, osteoporosis, osteodystrophy, etc. by strengthening bones.
상기 홍화씨는 추출용매 하에서 초음파처리를 통해 추출되는 것으로서, 구체적으로 홍화씨와 추출용매가 1 : 5 내지 25, 바람직하게는 1 : 10 내지 20의 중량비로 혼합되어 20 내지 50 kHz, 바람직하게는 30 내지 40 kHz의 진동수 및 50 내지 700 W, 바람직하게는 150 내지 400 W 파워의 초음파기로 20 내지 85 ℃, 바람직하게는 60 내지 80 ℃하에서 5 내지 30분, 바람직하게는 10 내지 20분 동안 처리된다. The safflower seeds are extracted through sonication under an extraction solvent, and specifically, the safflower seeds and the extraction solvent are mixed in a weight ratio of 1: 5 to 25, preferably 1: 10 to 20, and 20 to 50 kHz, preferably 30 to It is treated with an ultrasonicator with a frequency of 40 kHz and a power of 50 to 700 W, preferably 150 to 400 W, at 20 to 85° C., preferably 60 to 80° C. for 5 to 30 minutes, preferably 10 to 20 minutes.
홍화씨를 추출 시 초음파 추출이 아니라 열수 추출, 에탄올 등의 알코올 추출인 경우에는 유효성분이 소량 추출될 뿐만 아니라 항산화, 자외선 차단 및 블루라이트 차단효과가 낮을 수 있다.When extracting safflower seeds, in the case of hot water extraction or alcohol extraction such as ethanol, not ultrasonic extraction, not only a small amount of active ingredients are extracted, but also antioxidant, UV blocking and blue light blocking effects may be low.
상기 홍화씨와 추출용매의 중량비가 상기 범위를 벗어나는 경우에는 추출물에 홍화씨의 유효성분이 적은 양으로 추출될 수 있다. When the weight ratio of the safflower seed to the extraction solvent is out of the above range, the active ingredient of the safflower seed may be extracted in a small amount in the extract.
또한, 초음파기의 진동수 및 파워가 상기 하한치 미만인 경우에는 홍화씨의 유효성분이 적은 양으로 추출될 수 있으며, 상기 상한치 초과인 경우에는 유효성분 외에 다른 물질도 다량으로 추출되어 효과가 저하될 수 있다. In addition, when the frequency and power of the ultrasonicator are less than the lower limit, the active ingredient of safflower seed may be extracted in a small amount, and if it exceeds the upper limit, other substances in addition to the active ingredient are extracted in a large amount, thereby reducing the effect.
또한, 추출온도 및 추출시간이 상기 하한치 미만인 경우에는 홍화씨의 유효성분이 적은 양으로 추출될 수 있으며, 상기 상한치 초과인 경우에는 독성물질이 발생할 수 있다.In addition, when the extraction temperature and extraction time are less than the lower limit, the active ingredient of safflower seeds can be extracted in a small amount, and when it exceeds the upper limit, toxic substances may be generated.
상기 추출물을 추출하는 추출용매는 물, 탄소수 1 내지 4의 저급알코올, 에틸렌글리콜, 에틸에테르 또는 이들의 혼합용매이다. 상기 저급알코올로는 20 내지 99 부피%의 메탄올, 에탄올, 부탄올 또는 프로판올 수용액을 들 수 있으며, 바람직하게는 우수한 항산화, 자외선 차단 및 블루라이트 차단 효과를 위하여 50 내지 80 부피%의 에탄올 수용액을 들 수 있다.The extraction solvent for extracting the extract is water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. As the lower alcohol, 20 to 99% by volume of an aqueous solution of methanol, ethanol, butanol or propanol may be used, and preferably, an aqueous solution of 50 to 80% by volume of ethanol may be used for excellent antioxidant, UV protection and blue light blocking effects. there is.
본 발명의 홍화씨 초음파 추출물은 화장료 조성물 외에 건강기능식품에도 사용될 수 있다.The ultrasonic extract of safflower seeds of the present invention may be used in health functional foods in addition to cosmetic compositions.
또한, 본 발명은 반응표면분석법을 이용하여 홍화씨 초음파 추출물을 제조하는 방법을 제공한다.In addition, the present invention provides a method for preparing an ultrasonic extract of safflower seeds using a response surface analysis method.
본 발명의 반응표면분석법을 이용한 홍화씨 초음파 추출물의 제조방법은 (A) 홍화씨를 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매인 추출용매, 20 내지 85 ℃의 추출온도, 10 내지 60분의 추출시간 하에서 20 내지 50 kHz의 진동수 및 50 내지 700 W 파워의 초음파기로 추출한 후 원심분리하여 수득한 상등액의 총 폴리페놀에 대한 실험값을 획득하는 단계; (B) 상기 (A)단계의 실험값을 이용하여 하기 [수학식 1]로 표시되는 2차 회귀식 모델을 도출하는 단계; (C) 상기 (B)단계에서 도출된 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계; (D) 상기 (A)단계에서 수득한 상등액의 총 플라보노이드 함량에 대한 실험값을 획득하는 단계; (E) 상기 (D)단계의 실험값을 이용하여 하기 [수학식 2]로 표시되는 2차 회귀식 모델을 도출하는 단계; (F) 상기 (E)단계에서 도출된 2차 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계; (G) 상기 (A)단계에서 수득한 상등액의 DPPH 라디칼 소거능에 대한 실험값을 획득하는 단계; (H) 상기 (G)단계의 실험값을 이용하여 하기 [수학식 3]으로 표시되는 2차 회귀식 모델을 도출하는 단계; (I) 상기 (H)단계에서 도출된 2차 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계; 및 (J) 상기 (C), (F) 및 (I)단계에서 수득된 반응표면곡선을 겹치기기법(superimposing)으로 총 폴리페놀 함량, 총 플라보노이드 함량, DPPH 라디칼 소거능에 대한 공통의 최적화 조건을 예측하는 단계;를 포함한다. 이렇게 예측된 조건을 이용하여 홍화씨를 초음파 추출하면 DPPH 라디칼 소거능, 총 폴리페놀 함량 및 총 플라보노이드 함량에 대하여 우수한 효과를 보인다. The method for producing an ultrasonic extract of safflower seeds using the reaction surface analysis method of the present invention is (A) water, a lower alcohol having 1 to 4 carbon atoms, or an extraction solvent that is a mixed solvent thereof, an extraction temperature of 20 to 85 ℃, 10 to 60 minutes Obtaining experimental values for total polyphenols in the supernatant obtained by centrifugation after extraction with an ultrasonicator of a frequency of 20 to 50 kHz and a power of 50 to 700 W under an extraction time of ; (B) deriving a quadratic regression model represented by the following [Equation 1] using the experimental value of step (A); (C) verifying reliability by performing analysis of variance (ANOVA) on the regression model derived in step (B), and obtaining a response surface curve for the extraction conditions; (D) obtaining an experimental value for the total flavonoid content of the supernatant obtained in step (A); (E) deriving a quadratic regression model represented by the following [Equation 2] using the experimental value of step (D); (F) verifying reliability by performing analysis of variance (ANOVA) on the quadratic regression model derived in step (E), and obtaining a response surface curve for the extraction conditions; (G) obtaining an experimental value for the DPPH radical scavenging ability of the supernatant obtained in step (A); (H) deriving a quadratic regression model represented by the following [Equation 3] using the experimental values of the step (G); (I) verifying reliability by performing analysis of variance (ANOVA) on the quadratic regression model derived in step (H), and obtaining a response surface curve for the extraction conditions; and (J) predicting common optimization conditions for total polyphenol content, total flavonoid content, and DPPH radical scavenging ability by superimposing the response surface curves obtained in steps (C), (F) and (I) including; Ultrasonic extraction of safflower seeds using these predicted conditions shows excellent effects on DPPH radical scavenging ability, total polyphenol content and total flavonoid content.
[수학식 1][Equation 1]
YTPC=-4.81776-0.015551X1+0.28967X2+0.21412X3+6.72730E-005X1X2+6.01865E-004X1X3-1.00677E-003X2X3-1.23645E-004X1 2- 2.01372E-0.03X2 2-1.42821E-003X3 2 Y TPC =-4.81776-0.015551X 1 +0.28967X 2 +0.21412X 3 +6.72730E-005X 1 X 2 +6.01865E-004X 1 X 3 -1.00677E-003X 2 X 3 -1.23645E-004X 1 2 - 2.01372 E-0.03X 2 2 -1.42821E-003X 3 2
[수학식 2][Equation 2]
YTFC=-0.37372+9.55406E-003X1+9.20547E-003X2+2.05361E-003X3-9.72712E-005X1X2-5.20451E-005X1X3+5.37565E-005X2X3-1.77861E-005X1 2-4.02178E-005X2 2-1.79762E-005X3 2 Y TFC =-0.37372+9.55406E-003X 1 +9.20547E-003X 2 +2.05361E-003X 3 -9.72712E-005X 1 X 2 -5.20451E-005X 1 X 3 +5.37565E-005X 2 X 3 -1.77861E -005X 1 2 -4.02178E-005X 2 2 -1.79762E-005X 3 2
[수학식 3][Equation 3]
YDPPH=-16.21374-0.19557X1+0.64596X2+1.96052X3+5.50661E-004X1X2+2.93686E-003X1X3-3.62518E-003X2X3+4.25974E-004X1 2-2.87540E-003X2 2-0.013343X3 2 Y DPPH =-16.21374-0.19557X 1 +0.64596X 2 +1.96052X 3 +5.50661E-004X 1 X 2 +2.93686E-003X 1 X 3 -3.62518E-003X 2 X 3 +4.25974E-004X 1 2 -2.87540 E-003X 2 2 -0.013343X 3 2
상기 수학식 1 내지 3에서, YTPC는 총 폴리페놀 함량의 예측값(mg GAE/g DM), YTFC는 총 플라보노이드 함량의 예측값(mg QE/g DM), YDPPH는 DPPH 라디칼 소거능의 예측값(%), X1은 추출시간, X2는 추출온도, X3는 추출용매의 농도이다.In Equations 1 to 3, Y TPC is the predicted value of the total polyphenol content (mg GAE / g DM), Y TFC is the predicted value of the total flavonoid content (mg QE / g DM), Y DPPH is the predicted value of the DPPH radical scavenging ability ( %), X 1 is the extraction time, X 2 is the extraction temperature, and X 3 is the concentration of the extraction solvent.
본 발명에서 사용되는 용어 '추출물'은 상기 용매를 이용하여 홍화씨에 포함된 성분을 추출한 추출물, 이들로부터 분획한 분획물, 이들 추출물 또는 분획물을 추가적으로 농축한 농축물, 이를 정제 또는 분리한 정제물도 포함하고, 상기 추출물, 분획물, 농축물 또는 정제물을 건조한 건조물 또는 그를 분쇄한 분말을 포함하는 의미로 사용된다. The term 'extract' used in the present invention includes an extract obtained by extracting the components contained in safflower seeds using the solvent, a fraction fractionated therefrom, a concentrate obtained by additionally concentrating these extracts or fractions, and a purified or separated product. , is used in the sense of including a dried product of the extract, fraction, concentrate or purified product or a powder obtained by pulverizing the same.
상기 정제물의 제조를 위해 분자량 컷-오프 값을 갖는 한외 여과막을 통과시키거나, 또는 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 부가할 수 있다.For the production of the purified product, various additionally performed, such as passing through an ultrafiltration membrane having a molecular weight cut-off value, or separation by various chromatography (those prepared for separation according to size, charge, hydrophobicity or affinity) A purification method may be added.
한편, 본 명세서에서 용어 '유효성분으로 함유하는'이란 홍화씨 초음파 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 일예로, 상기 홍화씨 초음파 추출물은 10 내지 1500 ㎍/㎖, 바람직하게는 100 내지 1000 ㎍/㎖의 농도로 사용된다. 홍화씨 초음파 추출물은 천연물로서 과량 사용하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 홍화씨 초음파 추출물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.Meanwhile, in the present specification, the term 'contained as an active ingredient' means including an amount sufficient to achieve the efficacy or activity of the ultrasonic extract of safflower seeds. For example, the ultrasonic extract of safflower seeds is used at a concentration of 10 to 1500 μg/ml, preferably 100 to 1000 μg/ml. Since the ultrasonic extract of safflower seed is a natural product and there is no side effect to the human body even when used in excess, the upper limit of the quantitative upper limit of the ultrasonic extract of safflower seed contained in the composition of the present invention can be selected and carried out by those skilled in the art within an appropriate range.
본 발명의 화장료 조성물에는 상기의 화장료 조성물과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합할 수 있으며, 이러한 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한제, 정제수, 수용성 비타민, 지용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스 등을 들 수 있다.In the cosmetic composition of the present invention, in addition to the above cosmetic composition, other ingredients commonly formulated in cosmetics may be blended as needed. Examples of these blending ingredients include oil and fat ingredients, moisturizing agents, emollients, surfactants, organic and inorganic pigments, Organic powder, UV absorber, preservative, disinfectant, antioxidant, pH adjuster, alcohol, colorant, flavoring agent, blood circulation promoter, cooling agent, limiting agent, purified water, water-soluble vitamin, fat-soluble vitamin, polymer peptide, polymer polysaccharide, sphingolipid and seaweed an extract, etc. are mentioned.
본 발명의 화장료 조성물은 당업계에서 통상 사용되는 유화 제형 및 가용화 제형의 형태로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in the form of emulsified formulations and solubilized formulations commonly used in the art.
또한, 본 발명의 상기 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 안료 및 천연향료와 같은 통상적인 보조제 및 담체를 더 포함할 수 있다.In addition, the ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions in addition to the ingredients as active ingredients, for example, conventional adjuvants such as stabilizers, pigments and natural fragrances; It may further include a carrier.
본 발명의 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 미스트, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 자외선 차단크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 마스크팩, 프레스파우더, 루스파우더, 아이섀도우 등과 같은 화장품류와 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 등이 있다.Products to which the composition of the present invention can be added include, for example, mist, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, sunscreen cream , moisture cream, hand cream, foundation, essence, nourishing essence, mask pack, press powder, loose powder, eye shadow, etc., and soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydrocarbon, propane , butane or propellants such as dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty ester, polyethylene glycol or fatty acid ester of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상 희석제, 에톡실화이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, water, a liquid diluent such as ethanol or propylene glycol, ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
또한, 본 발명은 홍화씨 초음파 추출물을 유효성분으로 함유하는 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition containing safflower seed ultrasonic extract as an active ingredient.
건강기능식품이란, 홍화씨 초음파 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 홍화씨 초음파 추출물의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.Health functional food is a food prepared by adding ultrasonic safflower seed extract to food materials such as beverages, teas, spices, gum, and confectionery, or by encapsulating, powdering, or suspension, etc. However, unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be ingested on a daily basis. The amount of added safflower seed ultrasonic extract in such health functional food cannot be uniformly defined as it varies depending on the type of health functional food, but it can be added within a range that does not impair the original taste of the food, and is usually 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of a health functional food in the form of pills, granules, tablets or capsules, it is usually added in an amount of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
또한 본 발명은 피부암의 예방 또는 치료용 의약, 또는 동물용 의약 제조를 위한 홍화씨 초음파 추출물의 신규 용도를 제공한다.In addition, the present invention provides a novel use of the ultrasonic extract of safflower seeds for the prevention or treatment of skin cancer, or for the manufacture of a medicament for animals.
상기 '약학 조성물'또는 '의약'은 유효성분으로 홍화씨 초음파 추출물 이외에, 약학 조성물 등의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The 'pharmaceutical composition' or 'medicine' may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions, in addition to the ultrasonic extract of safflower seed as an active ingredient.
상기 '담체'는 세포 또는 조직 내로의 화합물의 부가를 용이하게 하는 화합물이다. 상기 '희석제'는 대상 화합물의 생물학적 활성 형태를 안정화시킬 뿐만 아니라, 화합물을 용해시키게 되는 물에서 희석되는 화합물이다. The 'carrier' is a compound that facilitates the addition of the compound into a cell or tissue. The 'diluent' is a compound that is diluted in water to not only stabilize the biologically active form of the compound of interest, but also to dissolve the compound.
상기 담체, 부형제 및 희석제로는 특별히 한정할 필요는 없으나 예를 들어, 유당, 포도당, 설탕, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다.The carrier, excipient and diluent are not particularly limited, but for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil.
상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약의 사용량은 환자 또는 치료대상 동물의 나이, 성별, 체중에 따라 달라질 수 있으며, 무엇보다도, 치료대상 개체의 상태, 치료 대상 질환의 특정한 카테고리 또는 종류, 투여 경로, 사용되는 치료제의 속성에 의존적일 것이다.The amount of the pharmaceutical composition, medicine, pharmaceutical composition for animals or veterinary medicine may vary depending on the age, sex, and weight of the patient or animal to be treated, and above all, the condition of the subject to be treated, a specific category of the disease to be treated, or It will depend on the type, route of administration, and the nature of the therapeutic agent used.
상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약은 체내에서 활성성분의 흡수도, 배설속도, 환자 또는 치료대상 동물의 연령 및 체중, 성별 및 상태, 치료할 질병의 중증정도 등에 따라 적절히 선택되나, 일반적으로 1일 0.1 내지 1,000 mg/kg, 바람직하게는 1 내지 500 mg/kg, 더욱 바람직하게는 5 내지 250 mg/kg, 가장 바람직하게는 10 내지 100 mg/kg으로 투여하는 것이 바람직하다. 이렇게 제형화 된 단위 투여형 제제는 필요에 따라 일정시간 간격으로 수회 투여할 수 있다.The pharmaceutical composition, medicament, pharmaceutical composition for animals or medicament for animals is appropriately selected according to the absorption rate of the active ingredient in the body, the rate of excretion, the age and weight of the patient or the animal to be treated, sex and condition, the severity of the disease to be treated, etc. , It is generally preferred to administer 0.1 to 1,000 mg/kg, preferably 1 to 500 mg/kg, more preferably 5 to 250 mg/kg, and most preferably 10 to 100 mg/kg per day. The unit dosage form formulated in this way can be administered several times at regular time intervals as needed.
상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약은 개별적으로 예방제 또는 치료제로서 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다.The pharmaceutical composition, medicament, pharmaceutical composition for animals or medicament for animals may be administered individually as a prophylactic or therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.
상기 약학조성물, 의약, 동물용 약학 조성물 또는 동물용 의약은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 트로키제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구 제형으로 제형화하여 사용될 수 있다. 제형화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The pharmaceutical composition, medicine, pharmaceutical composition for animals or medicine for animals may be formulated into oral dosage forms such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc. there is. In the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used.
경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제, 트로키제 등이 포함되며, 이러한 고형 제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트, 설탕 또는 유당, 젤라틴 등을 섞어 조제될 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, and the like, and such solid preparations include at least one excipient to the compound, for example, starch, calcium carbonate, sugar or lactose, gelatin. It can be prepared by mixing and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. .
상기 피부암의 치료방법은 인간, 또는 인간을 제외한 동물, 특히 포유동물에게 상기 조성물을 투여 하는 것으로, 예를 들어 피부암인 치료대상 개체에게 상기 조성물을 투여하는 것이다.The method for treating skin cancer is administering the composition to a human or non-human animal, particularly a mammal, for example, administering the composition to a subject to be treated, which is skin cancer.
상기 치료를 위한 투여량, 투여 방법 및 투여 횟수는 상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약의 투여량, 투여 방법 및 투여 횟수를 참고할 수 있다.The dosage, administration method, and frequency of administration for the treatment may refer to the dosage, administration method, and frequency of administration of the pharmaceutical composition, medicine, pharmaceutical composition for animals or medicament for animals.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.Hereinafter, preferred examples are presented to help the understanding of the present invention, but the following examples are merely illustrative of the present invention, and it will be apparent to those skilled in the art that various changes and modifications are possible within the scope and spirit of the present invention, It goes without saying that such variations and modifications fall within the scope of the appended claims.
실시예 1 내지 17. Examples 1 to 17.
홍화씨를 60 ℃ 열풍건조기(FC 49, Lab house, Korea)에서 16시간 건조하여 더 이상의 중량이 낮아지지 않는 것을 확인하고 건조한 시료를 분쇄기(HMF-3000S, Hanil, Korea)로 분쇄한 후 40-100 mesh의 여과망에 통과시켜 데시케이터에서 보관하였다. 상기 분쇄된 홍화씨와 농도가 상이한 에탄올 수용액을 1 : 20의 중량비로 혼합하여 초음파기(JAC Ultrasinic, Hwaseng, Korea)에 투입 후 초음파(40 kHz, 200 W)를 이용하여 추출하였다. 추출한 추출물을 원심분리기를 이용하여 고액분리(4 ℃, 5000 rpm, 3분)한 후 상등액만 이용하였다.After drying the safflower seeds at 60 ℃ in a hot air dryer (FC 49, Lab house, Korea) for 16 hours, it was confirmed that the weight did not decrease any more, and after pulverizing the dried sample with a grinder (HMF-3000S, Hanil, Korea), 40-100 It was passed through a mesh filter and stored in a desiccator. The pulverized safflower seeds and an aqueous ethanol solution having different concentrations were mixed in a weight ratio of 1:20, put into an ultrasonicator (JAC Ultrasinic, Hwaseng, Korea), and then extracted using ultrasonic waves (40 kHz, 200 W). The extracted extract was subjected to solid-liquid separation (4 °C, 5000 rpm, 3 minutes) using a centrifuge, and only the supernatant was used.
이때 추출 공정의 추출시간, 추출온도 및 에탄올 농도를 다르게 하여 각각의 추출물을 수득하였다. At this time, each extract was obtained by varying the extraction time, extraction temperature, and ethanol concentration of the extraction process.
비교예 1. 에탄올 추출물Comparative Example 1. Ethanol extract
홍화씨와 80 부피%의 에탄올 수용액을 1 : 20의 중량비로 혼합하여 80 ℃에서 45분간 동안 추출하여 홍화씨 에탄올 추출물을 수득하였다.Safflower seeds and 80% by volume of an aqueous ethanol solution were mixed in a weight ratio of 1:20 and extracted at 80° C. for 45 minutes to obtain an ethanol extract of safflower seeds.
비교예 2. 메탄올 추출물Comparative Example 2. Methanol extract
상기 비교예 1과 동일하게 실시하되, 50 부피%의 에탄올 수용액 대신 50 부피%의 메탄올 수용액을 이용하여 홍화씨 메탄올 추출물을 수득하였다.A methanol extract of safflower seed was obtained in the same manner as in Comparative Example 1, except that 50% by volume of an aqueous methanol solution was used instead of a 50% by volume aqueous solution of ethanol.
<시험예><Test Example>
실시예 1 내지 17 및 비교예 1 내지 2에 따라 제조된 추출물을 이용하여 항산화 지표인 DPPH 소거능, 총 폴리페놀, 총 플라보노이드를 측정하였다. DPPH scavenging ability, total polyphenols, and total flavonoids, which are antioxidant indicators, were measured using the extracts prepared according to Examples 1 to 17 and Comparative Examples 1 to 2.
시험예 1. DPPH 라디칼 소거능(DSA), 총 폴리페놀 함량(TPC), 총 플라보노이드 함량(TFC) 측정Test Example 1. Measurement of DPPH radical scavenging activity (DSA), total polyphenol content (TPC), and total flavonoid content (TFC)
중심합성계획법(central composite design, CCD)을 이용하여 추출시간(X1), 추출온도(X2), 용매농도(X3)에 대하여, 5단계의 -1.68, -1, 0, 1 및 1.68로 코드화하여 실험범위를 설계하고, 설계된 하기 19가지 조건에 대하여 실험하여 실험값을 수득하였다.5 steps of -1.68, -1, 0, 1 and 1.68 for extraction time (X 1 ), extraction temperature (X 2 ), and solvent concentration (X 3 ) using central composite design (CCD) The experimental range was designed by coding with , and experimental values were obtained by testing the following 19 conditions.
1-1. DPPH 라디칼 소거능(%): 2,2-diphenyl-1- picrylhydrazyl(DPPH) 라디칼 소거 활성 측정을 통해 항산화능을 측정하였다. DPPH는 비교적 안정한 프리 라디칼로써 ascorbic acid, tocopherol등에 의해 환원되어 짙은 자색이 탈색되는 원리를 이용하여 항산화 활성을 간단히 측정할 수 있다. 시료를 희석하고 희석한 시료 0.25 mL와 0.1 M DPPH 1.25 mL를 혼합한 후 실온에서 20분간 암실 보관한 다음 517 nm에서 흡광도를 측정하였다. 대조군으로는 ascorbic acid(CAS 50-81-7, Sigma, USA)를 이용하였고, 시료와 동일한 조건으로 진행하였다. 라디칼 소거능은 하기 [수학식 4]에 따라 계산하였다.1-1. DPPH radical scavenging activity (%): The antioxidant activity was measured by measuring 2,2-diphenyl-1- picrylhydrazyl (DPPH) radical scavenging activity. As a relatively stable free radical, DPPH can be reduced by ascorbic acid, tocopherol, etc. and its antioxidant activity can be measured simply by using the principle that dark purple is discolored. After diluting the sample and mixing 0.25 mL of the diluted sample with 1.25 mL of 0.1 M DPPH, it was stored in the dark at room temperature for 20 minutes, and then absorbance was measured at 517 nm. Ascorbic acid (CAS 50-81-7, Sigma, USA) was used as a control, and the same conditions as the samples were used. The radical scavenging ability was calculated according to the following [Equation 4].
[수학식 4][Equation 4]
라디칼 소거활성(%)=[1-(시료의 흡광도/대조군의 흡광도)]X100Radical scavenging activity (%)=[1-(absorbance of sample / absorbance of control)]X100
1-2. 총 폴리페놀 함량(mg GAE/g DM): Folin-Denis 법을 변형하여 측정하였다. 각 조건에서 확보된 추출물 0.14 mL에 0.2 N Folin-Ciocalteu 용액 0.7 mL 첨가한 반응액을 실온에서 8분 동안 방치한 후 7.5% Na₂CO₃ 0.56 mL를 가하여 상온에서 1시간 동안 반응시켰다. 이후 분광광도계(Optizen 2120UV, KLab. Ltd., DaeJun, Korea)를 이용하여 765 nm에서 흡광도를 측정하였으며, galic acid(Sigma-Aldrich, Minneapolis, USA)를 표준물질로 사용하여 검량선을 작성하고 추출물의 TPC 함량을 mg galic acid equivalent (GAE)/g dry matter (DM)로 표시하였다.1-2. Total polyphenol content (mg GAE/g DM) : It was determined by modifying the Folin-Denis method. To 0.14 mL of the extract obtained under each condition, 0.7 mL of 0.2 N Folin-Ciocalteu solution was added, and the reaction solution was left at room temperature for 8 minutes, then 0.56 mL of 7.5% Na₂CO₃ was added and reacted at room temperature for 1 hour. Then, the absorbance was measured at 765 nm using a spectrophotometer (Optizen 2120UV, KLab. Ltd., DaeJun, Korea), and a calibration curve was prepared using galic acid (Sigma-Aldrich, Minneapolis, USA) as a standard material, and the The TPC content was expressed as mg gallic acid equivalent (GAE)/g dry matter (DM).
1-3. 총 플라보노이드 함량(mg QE/g DM): Zhishen 등의 방법을 변형하여 사용하였다. 플라보노이드에 알칼리를 작용시키면 황색으로 발색되는 원리에 근거하여 흡광도를 측정해 TFC 농도를 측정하였다. 각 시료 0.5 mL에 증류수 2.5 mL와 99.5% (v/v) 에탄올 1.5 mL 가한 후 1 M potassium acetate 0.1 mL와 10% aluminum chloride 0.1 mL를 가하여 교반한 후 실온에서 30분 동안 방치하였다. 415 nm에서 흡광도를 측정하였으며 quercetin (Sigma-Aldrich, Minneapolis, USA)을 25, 50, 100, 200 ug/mL로 희석하여 검량선을 구하여 플라보노이드 함량을 mg quercetin equivalent (QE)/g dry matter (DM)로 나타내었다. 1-3. Total flavonoid content (mg QE/g DM): A modified method of Zhishen et al. was used. TFC concentration was measured by measuring absorbance based on the principle that yellow color develops when alkali is applied to flavonoids. To 0.5 mL of each sample, 2.5 mL of distilled water and 1.5 mL of 99.5% (v/v) ethanol were added, then 0.1 mL of 1 M potassium acetate and 0.1 mL of 10% aluminum chloride were added, stirred, and left at room temperature for 30 minutes. Absorbance was measured at 415 nm, and a calibration curve was obtained by diluting quercetin (Sigma-Aldrich, Minneapolis, USA) to 25, 50, 100, 200 ug/mL to determine the flavonoid content in mg quercetin equivalent (QE)/g dry matter (DM) indicated as
(min)extraction time
(min)
(℃)extraction temperature
(℃)
(부피%)ethanol concentration
(volume%)
상기 실시예 15 내지 17은 DPPH 라디칼 소거능(DSA), 총 폴리페놀 함량(TPC), 총 플라보노이드 함량(TFC)의 오차를 확인하기 위하여 동일한 조건에서 수행한 실험이다.Examples 15 to 17 are experiments performed under the same conditions to confirm errors in DPPH radical scavenging activity (DSA), total polyphenol content (TPC), and total flavonoid content (TFC).
위 표 1에 나타낸 바와 같이, 총 폴리페놀 함량에 대한 실험값은 실시예 10에 따라 제조된 추출물이 다른 군에 비하여 우수한 것을 확인하였으며, 총 플라보노이드 함량에 대한 실험값은 실시예 7이 다른 군에 비하여 우수한 것을 확인하였고, DPPH 라디칼 소거능에 대한 실험값은 실시예 8에 따라 제조된 추출물이 다른 군에 비하여 우수한 것을 확인하였다.As shown in Table 1 above, the experimental value for the total polyphenol content confirmed that the extract prepared according to Example 10 was superior to other groups, and the experimental value for the total flavonoid content was excellent in Example 7 compared to other groups It was confirmed that the experimental value for the DPPH radical scavenging ability was confirmed that the extract prepared according to Example 8 was superior to that of the other groups.
특히, 정제수(초음파)를 사용한 실시예 13, 에탄올 추출물인 비교예 1 및 메탄올 추출물인 비교예 2는 총 폴리페놀 함량, 총 플라보노이드 함량 및 DPPH 라디칼 소거능 모두 수치가 낮은 것을 확인하였다. In particular, in Example 13 using purified water (ultrasound), Comparative Example 1 which is an ethanol extract, and Comparative Example 2 which is a methanol extract, it was confirmed that the total polyphenol content, the total flavonoid content and the DPPH radical scavenging ability were all low.
DPPH 라디칼 소거능, 총 폴리페놀 함량 및 총 플라보노이드 함량이 모두 고르게 우수한 군은 실시예 8인 것을 확인하였다.The DPPH radical scavenging ability, the total polyphenol content and the total flavonoid content were all evenly excellent in Example 8.
상기 실험값들을 기반으로 Design Expert software(V.8.0, State-Ease, Inc, Minneapolis, USA)를 사용하여 최적조건을 예측하기 위하여 상기 [수학식 1] 내지 [수학식 3]과 같은 회귀식을 도출하였다.Based on the experimental values, a regression equation such as [Equation 1] to [Equation 3] is derived to predict the optimal condition using Design Expert software (V.8.0, State-Ease, Inc, Minneapolis, USA) did
시험예 2. 최적 조건 탐색Test Example 2. Search for optimal conditions
YTPC=-4.81776-0.015551X1+0.28967X2+0.21412X3+6.72730E-005X1X2+6.01865E-004X1X3-1.00677E-003X2X3-1.23645E-004X1 2- 2.01372E-0.03X2 2-1.42821E-003X3 2 [Equation 1]
Y TPC =-4.81776-0.015551X 1 +0.28967X 2 +0.21412X 3 +6.72730E-005X 1 X 2 +6.01865E-004X 1 X 3 -1.00677E-003X 2 X 3 -1.23645E-004X 1 2 - 2.01372 E-0.03X 2 2 -1.42821E-003X 3 2
YTFC=-0.37372+9.55406E-003X1+9.20547E-003X2+2.05361E-003X3-9.72712E-005X1X2-5.20451E-005X1X3+5.37565E-005X2X3-1.77861E-005X1 2-4.02178E-005X2 2-1.79762E-005X3 2 [Equation 2]
Y TFC =-0.37372+9.55406E-003X 1 +9.20547E-003X 2 +2.05361E-003X 3 -9.72712E-005X 1 X 2 -5.20451E-005X 1 X 3 +5.37565E-005X 2 X 3 -1.77861E -005X 1 2 -4.02178E-005X 2 2 -1.79762E-005X 3 2
YDPPH=-16.21374-0.19557X1+0.64596X2+1.96052X3+5.50661E-004X1X2+2.93686E-003X1X3-3.62518E-003X2X3+4.25974E-004X1 2-2.87540E-003X2 2-0.013343X3 2 [Equation 3]
Y DPPH =-16.21374-0.19557X 1 +0.64596X 2 +1.96052X 3 +5.50661E-004X 1 X 2 +2.93686E-003X 1 X 3 -3.62518E-003X 2 X 3 +4.25974E-004X 1 2 -2.87540 E-003X 2 2 -0.013343X 3 2
X1 : 추출시간(min); X2 : 추출온도(℃); X3 : 에탄올 농도(%); R 2 : Coefficient of Determination; p : probability valueX 1 : extraction time (min); X 2 : extraction temperature (℃); X 3 : ethanol concentration (%); R 2 : Coefficient of Determination; p : probability value
valueF
value
valueP
value
valueF
value
valueP
value
valueF
value
valueP
value
2-1. 총 폴리페놀 함량(TPC)에 미치는 조건 탐색2-1. Exploring conditions affecting total polyphenol content (TPC)
반응표면 분석법 중 하나인 중심합성계획법(central composite design, CCD)을 이용하여 도출된 조건에 따라 측정된 총 폴리페놀 함량(TPC)에 대한 실험값은 [표 1]에 나타냈다.The experimental values for the total polyphenol content (TPC) measured according to the conditions derived using the central composite design (CCD), one of the response surface analysis methods, are shown in [Table 1].
측정된 총 폴리페놀 함량(Total polyphenol content, TPC)에 따른 2차 회귀 방정식은 [표 2]를 통해 알 수 있으며, 위의 회귀 방정식의 결정계수인 R 2 값은 1에 가까울수록 적합성을 갖는 모델임을 인정한다. 측정값으로 얻어진 값을 기반으로 분산분석(Analysis of variance, ANOVA)을 통해 결과의 유의성을 평가하였을 때, 총 폴리페놀 함량에 대한 R 2 값은 0.9015로 도출된 함수가 총 폴리페놀 함량 예측에 적합한 모델이라고 판단된다. 또한 이에 따른 p-value값은 0.0086으로 p > 0.05 수준에서 유의성이 통계적으로 검증되었으며, 각 독립변수의 p-value값은 에탄올 농도(p = 0.0040), 추출 시간(p = 0.4431), 추출 온도(p = 0.9776) 순으로 결과 값에 영향을 주며 따라서 다른 독립변수에 비해 에탄올 농도가 총 폴리페놀 함량 결과에 영향을 주는 주된 요인임을 판단할 수 있다. The quadratic regression equation according to the measured total polyphenol content (TPC) can be found in [Table 2], and the R 2 value, the coefficient of determination of the above regression equation, is closer to 1, the more suitable the model. admit that When the significance of the result was evaluated through Analysis of variance (ANOVA) based on the value obtained as the measured value, the R 2 value for the total polyphenol content was 0.9015, and the function derived from it was suitable for predicting the total polyphenol content considered to be a model. In addition, the corresponding p -value was 0.0086, and significance was statistically verified at the level of p > 0.05, and the p-value of each independent variable was the ethanol concentration ( p = 0.0040), extraction time ( p = 0.4431), and extraction temperature ( p = 0.9776) affects the result value in that order, so it can be judged that the ethanol concentration is the main factor affecting the total polyphenol content result compared to other independent variables.
이는 일변수 곡선인 [도 1]을 통해서도 확인해볼 수 있으며, 이는 도출된 회귀방정식을 기반으로 독립변수 중 두 개의 값을 중간값에 고정된 상태로 하나의 변수를 변화시켜 최적화 그래프로 시각화한 것이다. [도 2]는 한 개의 독립변수를 중간값에 고정한 후 나머지 독립변수를 동시에 변화시켜 시각화한 3차원 반응표면곡선이다.This can also be confirmed through the univariate curve [Fig. 1], which is visualized as an optimization graph by changing one variable while fixing two values of the independent variables to the median value based on the derived regression equation. . [Fig. 2] is a three-dimensional response surface curve visualized by fixing one independent variable to the median value and then changing the remaining independent variables at the same time.
[도 1]에 도시된 것을 통하여 추출 온도와 에탄올 농도에서 급격히 증가하였다가 감소하는 경향을 확인할 수 있으며, [도 2A]에 도시된 것을 통하여 추출 온도가 증가할수록 총 폴리페놀 함량도 증가하는 것을 확인할 수 있었고, [도 2B]를 통해 추출 시간과 에탄올 농도가 증가함에 따라 총 폴리페놀 함량도 증가하였다가 급격히 감소하는 것을 확인하였다. 또한 에탄올 농도에 비해 추출 시간에서는 중간값에서 총 폴리페놀 함량이 최대값을 보이고 급격히 감소하는 경향을 보였다.It can be confirmed that the extraction temperature and the ethanol concentration sharply increase and then decrease through what is shown in [FIG. 1], and it can be confirmed that the total polyphenol content also increases as the extraction temperature increases through that shown in [FIG. 2A]. It was confirmed through [Fig. 2B] that the total polyphenol content also increased and then rapidly decreased as the extraction time and ethanol concentration increased. In addition, compared to the ethanol concentration, the total polyphenol content showed a maximum value at the median value in the extraction time and showed a tendency to decrease rapidly.
2-2. 총 플라보노이드 함량(TFC)에 미치는 조건 탐색2-2. Exploring conditions affecting total flavonoid content (TFC)
반응표면 분석법 중 하나인 중심합성계획법(central composite design, CCD)을 이용하여 도출된 조건에 따라 측정된 총 플라보노이드 함량(TFC)에 대한 실험값은 [표 1]에 나타냈다. The experimental values for the total flavonoid content (TFC) measured according to the conditions derived using the central composite design (CCD), one of the response surface analysis methods, are shown in [Table 1].
측정된 총 플라보노이드 함량(total flavonoid content, TFC)에 따른 2차 회귀 방정식은 [표 2]를 통해 알 수 있으며, 위의 회귀 방정식의 결정계수인 R 2 값은 1에 가까울수록 적합성을 갖는 모델임을 인정한다. 측정값으로 얻어진 값을 기반으로 분산분석(Analysis of variance, ANOVA)을 통해 결과의 유의성을 평가하였을 때, 총 플라보노이드 함량에 대한 R 2 값은 0.8432로 도출된 함수가 TFC 예측에 적합한 모델이라고 판단된다. 또한 이에 따른 p-value값은 0.0362로 p > 0.05 수준에서 유의성이 통계적으로 검증되었으며, 각 독립변수의 p-value값은 추출 시간(p = 0.0023)의 유의성이 가장 높은 것으로 나타났으며 에탄올 농도(p = 0.0146), 추출 온도(p = 0.9687)의 유의성은 추출 시간에 비해 유의성이 낮게 확인되었다. 따라서 다른 독립변수에 비해 추출 시간이 총 플라보노이드 함량 결과에 영향을 주는 주된 요인임을 판단할 수 있다.The quadratic regression equation according to the measured total flavonoid content (TFC) can be found in [Table 2], and the R 2 value, the coefficient of determination of the regression equation above, is a model with better fit as it is closer to 1. admit it When the significance of the results was evaluated through Analysis of Variance (ANOVA) based on the values obtained as measured values, the R 2 value for the total flavonoid content was determined to be 0.8432, which is a model suitable for TFC prediction. . In addition, the corresponding p -value was 0.0362, and the significance was statistically verified at the level of p > 0.05. The p -value of each independent variable showed the highest significance in the extraction time ( p = 0.0023), and the ethanol concentration ( The significance of p = 0.0146) and extraction temperature ( p = 0.9687) was confirmed to be low compared to the extraction time. Therefore, it can be determined that extraction time is the main factor affecting the result of total flavonoid content compared to other independent variables.
[도 3]은 추출 시간, 추출 온도 및 에탄올 농도의 세 가지 독립변수 중 두 개의 독립변수를 중앙값 0에 고정하여 하나의 독립변수 변동에 따른 총 플라보노이드 함량의 변화를 확인할 수 있는 일변수 곡선이고, [도 4]는 한 개의 독립변수를 중간값에 고정한 후 나머지 독립변수 동시에 변화시켜 시각화한 3차원 반응표면곡선이다.[Figure 3] is a univariate curve that can confirm the change in the total flavonoid content according to the change of one independent variable by fixing two independent variables among the three independent variables of extraction time, extraction temperature, and ethanol concentration to the median 0, [Fig. 4] is a three-dimensional response surface curve visualized by fixing one independent variable to the median value and then changing the remaining independent variables at the same time.
[도 3]에 도시된 바와 같이, 두 개의 독립변수는 중앙값 0에 고정하여 일변수의 변화를 확인하였을 때 총 플라보노이드 함량에 가장 큰 영향을 미치는 주요인은 추출 시간으로 확인하였다.As shown in [Fig. 3], when the two independent variables were fixed at the median 0 and the change of one variable was confirmed, the main factor that had the greatest effect on the total flavonoid content was the extraction time.
[도 4]에 도시된 것을 보았을 때, 추출 시간의 영향을 나타내는 [도 4A]와 [도 4B]는 추출 시간이 증가 할수록 총 플라보노이드 함량이 증가하는 것을 확인할 수 있었다. 또한 추출 시간의 영향을 나타내지 않은 [도 4C]에서는 일정한 추출 온도와 에탄올 농도에서 총 플라보노이드 함량을 최대로 나타낸 후 감소하는 양상을 보였다.As shown in [Fig. 4], [Fig. 4A] and [Fig. 4B] showing the effect of extraction time, it was confirmed that the total flavonoid content increased as the extraction time increased. In addition, in [Fig. 4C], which did not show the effect of extraction time, the total flavonoid content was maximally reduced at a constant extraction temperature and ethanol concentration, and then decreased.
2-3. DPPH 라디칼 소거능(DSA)에 미치는 조건 탐색2-3. Exploration of conditions affecting DPPH radical scavenging capacity (DSA)
반응표면 분석법 중 하나인 중심합성계획법(central composite design, CCD)을 이용하여 도출된 조건에 따라 측정된 DPPH 라디칼 소거능(DSA)에 대한 실험값은 [표 1]에 나타냈다.Experimental values for DPPH radical scavenging ability (DSA) measured according to conditions derived using central composite design (CCD), one of the response surface analysis methods, are shown in [Table 1].
측정된 DPPH 라디칼 소거능(DSA)에 따른 2차 회귀 방정식은 [표 2]를 통해 알 수 있으며, 위의 회귀 방정식의 결정계수인 R 2 값은 1에 가까울수록 적합성을 갖는 모델임을 인정한다. 측정값으로 얻어진 값을 기반으로 분산분석(Analysis of variance, ANOVA)을 통해 결과의 유의성을 평가하였을 때, DPPH 라디칼 소거능(DSA)에 대한 R 2 값은 0.9020 도출된 함수가 TFC 예측에 적합한 모델이라고 판단된다. 또한 이에 따른 p-value값은 0.0362로 p > 0.05 수준에서 유의성이 통계적으로 검증되었다.The quadratic regression equation according to the measured DPPH radical scavenging ability (DSA) can be found in [Table 2], and it is recognized that the closer the R 2 value of the regression equation above is to 1, the more suitable the model is. When the significance of the result was evaluated through analysis of variance (ANOVA) based on the value obtained as the measured value, the R 2 value for DPPH radical scavenging ability (DSA) was 0.9020, indicating that the derived function is a suitable model for TFC prediction. is judged In addition, the corresponding p -value was 0.0362, which was statistically verified for significance at the level of p > 0.05.
또한 각 독립변수의 p-value값을 확인하였을 때 추출 시간(p = 0.2875), 추출 온도(p =0.9519), 에탄올 농도(p = 0.0004)로 결과에 대한 영향은 추출 온도가 가장 미비하지만 추출 시간 역시 크게 영향을 미치지 않아 차이가 크지 않다. 따라서 에탄올 농도의 영향이 가장 크게 나타나는 것을 볼 수 있으며 이는 일변수 곡선 [도 5]를 통해 에탄올 농도의 곡선이 급격한 것을 통해 p값에 따른 해석과 같은 것으로 확인 할 수 있다. 또한 하나의 독립변수를 중간값에 고정한 후 나머지 독립변수를 동시에 변화시켜 시각화한 3차원 반응표면곡선은 [도 6]에 나타나있다.Also, when the p -value of each independent variable was checked, the extraction time ( p = 0.2875), extraction temperature ( p = 0.9519), and ethanol concentration ( p = 0.0004) had the slightest effect on the results, but the extraction time Also, there is no significant difference. Therefore, it can be seen that the effect of the ethanol concentration is the largest, and it can be confirmed that the ethanol concentration curve is sharp through the univariate curve [Fig. 5], which is the same as the interpretation according to the p value. In addition, after fixing one independent variable to the median value, the three-dimensional response surface curve visualized by changing the remaining independent variables at the same time is shown in FIG. 6 .
[도 6]에 도시된 바와 같이, 추출 시간과 추출 온도의 영향을 나타낸 [도 6A]는 곡선이 완만하여 두 독립변수에 의한 영향이 DPPH라디칼 소거능(DSA) 결과 값에 유의미한 차이를 주지 않는다는 것을 확인 할 수 있었다. 또한 [도 6B]와 [도 6C]를 통해서는 에탄올 농도가 높아짐에 따라 DPPH라디칼 소거능(DSA)이 증가하는 것을 확인 할 수 있어 에탄올 농도가 결과 값에 유의적인 차이를 주는 것으로 확인할 수 있다.As shown in [Fig. 6], [Fig. 6A], which shows the effect of extraction time and extraction temperature, shows that the curve is gentle, so that the effect of the two independent variables does not have a significant difference in the DPPH radical scavenging ability (DSA) result value. could check In addition, it can be confirmed that the DPPH radical scavenging activity (DSA) increases as the ethanol concentration increases through [FIG. 6B] and [FIG. 6C], and it can be confirmed that the ethanol concentration gives a significant difference to the result value.
2-4. 최적조건 탐색2-4. Optimal condition search
홍화씨 초음파 추출물에 있어 항산화의 개별 최적화 결과를 바탕으로 Design Expert를 이용하여 반응표면곡선을 겹치기기법(superimposing)으로 3개 변수의 공통 최적화 조건을 예측하였다. In the ultrasonic extract of safflower seed, the common optimization conditions of three variables were predicted by superimposing the response surface curves using Design Expert based on the results of individual optimization of antioxidants.
이때 독립변수 중 에탄올 농도를 고정한 채로 DSA, TPC, TFC의 저해 활성 최적점을 확보하는 한편, 추출 공정 중의 비용을 최소화하여 경제성을 확보하고자 추출 시간과 추출 온도의 값이 가장 낮은 지점을 최적점으로 선정하였다. 이때 홍화씨 초음파 추출의 최적 추출 조건은 80.0%의 에탄올 농도에서 79.38 ℃온도로 35.38분 동안 추출한 것으로 예측되었고, 이때 종속변수인 DPPH 라디칼 소거능은 68.83%, 총 폴리페놀 함량은 8.27 mg GAE/g DM, 총 플라보노이드 함량은 0.39 mg QE/g DM으로 나타났다.At this time, in order to secure the optimum point of inhibitory activity of DSA, TPC, and TFC while fixing the ethanol concentration among the independent variables, and to secure economic feasibility by minimizing the cost during the extraction process, the point with the lowest values of extraction time and extraction temperature was set as the optimum point. was selected. At this time, the optimal extraction conditions for ultrasonic extraction of safflower seeds were predicted to be extracted for 35.38 minutes at a temperature of 79.38 ° C in an ethanol concentration of 80.0%, and the DPPH radical scavenging ability as a dependent variable was 68.83%, and the total polyphenol content was 8.27 mg GAE/g DM, Total flavonoid content was found to be 0.39 mg QE/g DM.
시험예 3. 자외선 차단율Test Example 3. UV protection rate
실시예 8, 실시예 13 및 비교예에 따라 제조된 홍화씨 초음파 추출물의 자외선 차단율을 측정하기 위하여 UV/Vis spectrophotometer를 이용하여 자외선 A (320-400 nm)와 지외선 B (290-320 nm) 파장범위에서 차단율을 측정하였고 이를 증류수와 대표적인 폴리페놀인 탄닌 10 mg/mL로의 자외선 차단능과 비교하여 흡광도를 측정하였다. UV A (320-400 nm) and UV B (290-320 nm) wavelengths using a UV/Vis spectrophotometer to measure the UV blocking rate of the ultrasonic extracts of safflower seeds prepared according to Examples 8, 13 and Comparative Examples. The blocking rate was measured in the range, and the absorbance was measured by comparing it with the UV blocking ability of distilled water and
증류수 대비UV-A blocking rate (%)
Distilled water vs.
증류수 대비UV-B blocking rate (%)
Distilled water vs.
타닌 대비UV-A blocking rate (%)
tannin contrast
타닌 대비UV-B blocking rate (%)
tannin contrast
위 표 4에 나타낸 바와 같이, 본 발명의 실시예 8에 따라 제조된 홍화씨 초음파 추출물은 정제수(초음파)를 사용한 실시예 13, 에탄올 추출물인 비교예 1 및 메탄올 추출물인 비교예 2에 비하여 자외선 흡수율이 높으므로 피부에 닿는 자외선 차단에 효과이다.As shown in Table 4 above, the ultrasonic wave extract of safflower seed prepared according to Example 8 of the present invention has a UV absorption rate compared to Example 13 using purified water (ultrasound), Comparative Example 1, which is an ethanol extract, and Comparative Example 2, which is a methanol extract. Because it is high, it is effective in blocking UV rays that come in contact with the skin.
즉, 피부에 도포된 화장료 조성물에서 자외선을 흡수하므로 피부에 직접적으로 닿는 자외선은 거의 없다. That is, since the cosmetic composition applied to the skin absorbs ultraviolet rays, there is almost no ultraviolet rays that directly touch the skin.
시험예 4. 블루라이트 차단율 측정Test Example 4. Blue light blocking rate measurement
실시예 8, 실시예 13 및 비교예에 따라 제조된 홍화씨 초음파 추출물에 대하여 블루라이트에 대한 차단율을 평가하기 위하여 UV 스펙트럼을 측정하여 차단율을 spectrophotometer (Optizen 2120UV, Mecasys Co., Korea)를 사용하여 측정하였다. 상기 실시예 8, 실시예 13 및 비교예에 따라 제조된 홍화씨 초음파 추출물을 UV spectrophotometer를 이용하여 파장범위 380∼500 nm에서 흡광도를 측정하였고 이를 증류수와 대표적인 폴리페놀인 탄닌 10 mg/mL로의 블루라이트 차단능과 비교하여 타닌 대비 블루라이트 차단율 증감값을 측정하였다. In order to evaluate the blocking rate against blue light for the ultrasonic extracts of safflower seeds prepared according to Examples 8, 13 and Comparative Examples, the UV spectrum was measured and the blocking rate was measured using a spectrophotometer (Optizen 2120UV, Mecasys Co., Korea). did. The absorbance of the ultrasonic extract of safflower seeds prepared according to Examples 8, 13 and Comparative Example was measured in a wavelength range of 380 to 500 nm using a UV spectrophotometer, and the absorbance was measured with distilled water and a representative polyphenol, tannin 10 mg/mL. Compared with the blocking ability, the increase/decrease value of the blue light blocking rate compared to tannin was measured.
타닌 대비Blue light blocking rate (%)
tannin contrast
위 표 5에 나타낸 바와 같이, 본 발명의 실시예 8에 따라 제조된 홍화씨 초음파 추출물은 정제수(초음파)를 사용한 실시예 13, 에탄올 추출물인 비교예 1 및 메탄올 추출물인 비교예 2에 비하여 블루라이트 차단율이 높으므로 피부에 닿는 블루라이트 차단에 효과적이다.As shown in Table 5 above, the safflower seed ultrasonic extract prepared according to Example 8 of the present invention has a blue light blocking rate compared to Example 13 using purified water (ultrasound), Comparative Example 1 which is an ethanol extract, and Comparative Example 2 which is a methanol extract. Because it is high, it is effective in blocking blue light that touches the skin.
즉, 피부에 도포된 화장료 조성물에서 블루라이트를 차단하므로 피부에 직접적으로 닿는 블루라이트는 거의 없다. That is, since the cosmetic composition applied to the skin blocks blue light, there is almost no blue light that directly touches the skin.
시험예 5. 피부암세포에 대한 독성Test Example 5. Toxicity to skin cancer cells
인간 흑색종 세포 생존율은 MTT 염색 방법에 의해 수행되었다 (J Immunol Methods, 141, 15-22, 1991). 인간 흑색종 세포를 96-웰 플레이트에 2X104 세포/웰의 밀도로 분주하여 24시간 안정화시킨 후 실험하였다. 각 웰의 배지 용량은 0.1 mL로 동일하게 만들었다. 실험군에는 각각의 추출물을 디메틸술폭시드(DMSO)에 녹여 1, 2, 4, 8 mg/mL 농도로 첨가하였고 대조군에는 추출물을 첨가하지 않고 DMSO만 넣어 24시간 배양하였다. 이때 최종 DMSO 함량은 0.5%가 되도록 하였다. 24시간이 지난 후 10 ㎕의 MTT(5 mg MTT/1 mL in PBS)를 배지에 첨가하고, 2시간 더 인간 흑색종 세포를 배양하였다. 각 웰에서 배지를 제거한 후, 100 ㎕ DMSO를 넣어 환원된 MTT 결정을 용해하기 위해 피펫팅으로 혼합하였다. 540 nm 필터를 가진 마이크로플레이트 리더(Powerwave XS, Bio-tek)로 각 웰에 대하여 스캐닝하여 발광되는 형광을 측정함으로써, 상대적인 인간 흑색종 세포 생존율을 계산하였다.Human melanoma cell viability was performed by the MTT staining method (J Immunol Methods, 141, 15-22, 1991). Human melanoma cells were seeded in a 96-well plate at a density of 2X10 4 cells/well, and the experiment was performed after stabilization for 24 hours. The medium volume of each well was made equal to 0.1 mL. To the experimental group, each extract was dissolved in dimethyl sulfoxide (DMSO) and added at a concentration of 1, 2, 4, and 8 mg/mL. In the control group, only DMSO was added without adding the extract and cultured for 24 hours. At this time, the final DMSO content was set to 0.5%. After 24 hours, 10 μl of MTT (5 mg MTT/1 mL in PBS) was added to the medium, and human melanoma cells were further cultured for 2 hours. After removing the medium from each well, 100 μl DMSO was added and mixed by pipetting to dissolve the reduced MTT crystals. Relative human melanoma cell viability was calculated by measuring the emitted fluorescence by scanning each well with a microplate reader (Powerwave XS, Bio-tek) with a 540 nm filter.
위 표 6에 나타낸 바와 같이, 본 발명의 실시예 8에 따라 제조된 홍화씨 초음파 추출물은 정제수(초음파)를 사용한 실시예 13, 에탄올 추출물인 비교예 1 및 메탄올 추출물인 비교예 2에 비하여 흑색종 세포의 사멸율이 높은 것을 확인하였다. 이에 따라 본 발명의 실시예 8에 따라 제조된 홍화씨 초음파 추출물은 피부암의 예방, 치료 또는 개선이 가능하다.As shown in Table 6 above, the safflower seed ultrasonic extract prepared according to Example 8 of the present invention was melanoma cells compared to Example 13 using purified water (ultrasound), Comparative Example 1 which was an ethanol extract, and Comparative Example 2 which was a methanol extract. It was confirmed that the mortality rate of Accordingly, the ultrasonic extract of safflower seed prepared according to Example 8 of the present invention can prevent, treat or improve skin cancer.
아래에 본 발명의 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a formulation example of a composition containing the extract of the present invention will be described, but the present invention is not intended to limit it, but to describe it in detail.
제제예 1: 산제의 제조Formulation Example 1: Preparation of powder
실시예 8의 추출물 분말 20 mg20 mg of extract powder of Example 8
유당 100 mgLactose 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight bag to prepare a powder.
제제예 2: 정제의 제조Formulation Example 2: Preparation of tablets
실시예 8의 추출물 분말 10 mg10 mg of extract powder of Example 8
옥수수전분 100 mg100 mg cornstarch
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional manufacturing method of tablets.
제제예 3: 캡슐제의 제조Formulation Example 3: Preparation of capsules
실시예 8의 추출물 분말 10 mg10 mg of extract powder of Example 8
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mg0.2 mg magnesium stearate
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled in a gelatin capsule to prepare a capsule.
제제예 4: 과립제의 제조Formulation Example 4: Preparation of granules
실시예 8의 추출물 분말 1,000 mg1,000 mg of extract powder of Example 8
비타민 혼합물 적량appropriate amount of vitamin mixture
비타민 A 아세테이트 70 ㎍70 μg vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mg0.5 mg of vitamin B6
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 mg
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 mgNicotinamide 1.7 mg
엽산 50 ㎍50 μg of folic acid
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture appropriate amount
황산제1철 1.75 mgferrous sulfate 1.75 mg
산화아연 0.82 mgZinc Oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgpotassium phosphate monobasic 15 mg
제2인산칼슘 55 mgDibasic calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg100 mg of calcium carbonate
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 건강기능식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is mixed with ingredients suitable for health functional food in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the ingredients are mixed according to a conventional health functional food manufacturing method. Next, the granules can be prepared and used in the preparation of a health functional food composition according to a conventional method.
제제예 5: 음료 제형의 제조Formulation Example 5: Preparation of beverage formulations
실시예 8의 추출물 분말 1,000 mg1,000 mg of extract powder of Example 8
구연산 1,000 mg1,000 mg citric acid
올리고당 100 g100 g of oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 mLAdd purified water to total 900 mL
통상의 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. After mixing the above ingredients according to a conventional beverage manufacturing method, after stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then refrigerated. used in the manufacture of functional beverage compositions.
본 발명을 적용하기에 적합한 화장료 조성물의 제조예를 제시하기로 한다.A preparation example of a cosmetic composition suitable for applying the present invention will be presented.
제조예 6: 화장수Preparation 6: lotion
실시예 8의 초음파 추출물을 포함하는 화장료 중 화장수의 제조예는 하기 표 7과 같다.Preparation examples of the lotion among the cosmetics containing the ultrasonic extract of Example 8 are shown in Table 7 below.
제조예 7: 로션Preparation Example 7: Lotion
실시예 8의 초음파 추출물을 포함하는 화장료 중 로션의 제조예는 하기 표 8과 같다.Preparation examples of the lotion in the cosmetic containing the ultrasonic extract of Example 8 are shown in Table 8 below.
제조예 8: 영양 크림Preparation 8: Nourishing Cream
실시예 8의 초음파 추출물을 포함하는 화장료 중 영양 크림의 제조예는 하기 표 9와 같다.Preparation examples of the nutritional cream in the cosmetic containing the ultrasonic extract of Example 8 are shown in Table 9 below.
제조예 9: 에센스Preparation Example 9: Essence
실시예 8의 초음파 추출물을 포함하는 화장료 중 에센스의 제조예는 하기 표 10과 같다.Preparation examples of the essence in the cosmetics containing the ultrasonic extract of Example 8 are shown in Table 10 below.
제조예 10: 마스크 팩용 유액Preparation 10: Emulsion for mask pack
실시예 8의 초음파 추출물을 포함하는 화장료 중 마스크 팩용 유액의 제조예는 하기 표 11과 같다.Preparation examples of the emulsion for a mask pack among cosmetics containing the ultrasonic extract of Example 8 are shown in Table 11 below.
Claims (10)
상기 홍화씨 초음파 추출물은 홍화씨와 80 부피%의 에탄올 수용액을 60 내지 80 ℃의 추출온도 하에서 20 내지 50 kHz의 진동수 및 50 내지 700 W 파워의 초음파기로 45분 동안 처리되어 수득된 것을 특징으로 하는 항산화, 자외선 차단 및 블루라이트 차단용 화장료 조성물.Contains safflower seed ultrasonic extract as an active ingredient,
The safflower seed ultrasonic extract is an antioxidant, characterized in that it is obtained by processing safflower seeds and 80% by volume of an ethanol aqueous solution at an extraction temperature of 60 to 80 ° C with a frequency of 20 to 50 kHz and an ultrasonicator of 50 to 700 W power for 45 minutes. A cosmetic composition for blocking UV rays and blocking blue light.
상기 홍화씨 초음파 추출물은 홍화씨와 80 부피%의 에탄올 수용액을 60 내지 80 ℃의 추출온도 하에서 20 내지 50 kHz의 진동수 및 50 내지 700 W 파워의 초음파기로 45분 동안 처리되어 수득된 것을 특징으로 하는 항산화, 자외선 차단 및 블루라이트 차단용 건강기능식품.Contains safflower seed ultrasonic extract as an active ingredient,
The safflower seed ultrasonic extract is an antioxidant, characterized in that it is obtained by processing safflower seeds and 80% by volume of an ethanol aqueous solution at an extraction temperature of 60 to 80 ° C with a frequency of 20 to 50 kHz and an ultrasonicator of 50 to 700 W power for 45 minutes. Health functional food for UV protection and blue light blocking.
(B) 상기 (A)단계의 실험값을 이용하여 하기 [수학식 1]로 표시되는 2차 회귀식 모델을 도출하는 단계;
(C) 상기 (B)단계에서 도출된 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계;
(D) 상기 (A)단계에서 수득한 상등액의 총 플라보노이드 함량에 대한 실험값을 획득하는 단계;
(E) 상기 (D)단계의 실험값을 이용하여 하기 [수학식 2]로 표시되는 2차 회귀식 모델을 도출하는 단계;
(F) 상기 (E)단계에서 도출된 2차 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계;
(G) 상기 (A)단계에서 수득한 상등액의 DPPH 라디칼 소거능에 대한 실험값을 획득하는 단계;
(H) 상기 (G)단계의 실험값을 이용하여 하기 [수학식 3]으로 표시되는 2차 회귀식 모델을 도출하는 단계;
(I) 상기 (H)단계에서 도출된 2차 회귀식 모델을 변량분석(ANOVA)하여 신뢰도를 입증하고 상기 추출조건에 대한 반응표면곡선을 수득하는 단계; 및
(J) 상기 (C), (F) 및 (I)단계에서 수득된 반응표면곡선을 겹치기기법(superimposing)으로 총 폴리페놀 함량, 총 플라보노이드 함량, DPPH 라디칼 소거능에 대한 공통의 최적화 조건을 예측하는 단계;를 포함하며,
상기 DPPH 라디칼 소거능, 총 폴리페놀 함량 및 총 플라보노이드 함량에 대한 공통의 최적화 조건에 따른 추출조건은 추출 시간 35.38분, 추출 온도 79.38 ℃ 및 에탄올 농도 80 부피%인 것을 특징으로 하는 반응표면분석법을 이용한 항산화용 홍화씨 초음파 추출물의 제조방법;
[수학식 1]
YTPC=-4.81776-0.015551X1+0.28967X2+0.21412X3+6.72730E-005X1X2+6.01865E-004X1X3-1.00677E-003X2X3-1.23645E-004X1 2- 2.01372E-0.03X2 2-1.42821E-003X3 2
[수학식 2]
YTFC=-0.37372+9.55406E-003X1+9.20547E-003X2+2.05361E-003X3-9.72712E-005X1X2-5.20451E-005X1X3+5.37565E-005X2X3-1.77861E-005X1 2-4.02178E-005X2 2-1.79762E-005X3 2
[수학식 3]
YDPPH=-16.21374-0.19557X1+0.64596X2+1.96052X3+5.50661E-004X1X2+2.93686E-003X1X3-3.62518E-003X2X3+4.25974E-004X1 2-2.87540E-003X2 2-0.013343X3 2
상기 수학식 1 내지 3에서, YTPC는 총 폴리페놀 함량의 예측값(mg GAE/g DM), YTFC는 총 플라보노이드 함량의 예측값(mg QE/g DM), YDPPH는 DPPH 라디칼 소거능의 예측값(%), X1은 추출시간, X2는 추출온도, X3는 추출용매의 농도임.(A) Safflower seeds in water, an extraction solvent that is a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, an extraction temperature of 20 to 85 ° C., a frequency of 20 to 50 kHz and a frequency of 50 to 700 W under an extraction time of 10 to 60 minutes obtaining experimental values for total polyphenols in the supernatant obtained by centrifugation after extraction with a power sonicator;
(B) deriving a quadratic regression model represented by the following [Equation 1] using the experimental value of step (A);
(C) verifying reliability by performing analysis of variance (ANOVA) on the regression model derived in step (B), and obtaining a response surface curve for the extraction conditions;
(D) obtaining an experimental value for the total flavonoid content of the supernatant obtained in step (A);
(E) deriving a quadratic regression model represented by the following [Equation 2] using the experimental value of step (D);
(F) verifying reliability by performing analysis of variance (ANOVA) on the quadratic regression model derived in step (E), and obtaining a response surface curve for the extraction conditions;
(G) obtaining an experimental value for the DPPH radical scavenging ability of the supernatant obtained in step (A);
(H) deriving a quadratic regression model represented by the following [Equation 3] using the experimental values of the step (G);
(I) verifying reliability by performing analysis of variance (ANOVA) on the quadratic regression model derived in step (H), and obtaining a response surface curve for the extraction conditions; and
(J) Predicting common optimization conditions for total polyphenol content, total flavonoid content, and DPPH radical scavenging ability by superimposing the response surface curves obtained in steps (C), (F) and (I) above step; including,
The extraction conditions according to the common optimization conditions for the DPPH radical scavenging ability, the total polyphenol content and the total flavonoid content are an extraction time of 35.38 minutes, an extraction temperature of 79.38 ° C. and an ethanol concentration of 80% by volume Antioxidation using a reaction surface analysis method A method for preparing an ultrasonic extract of safflower seeds;
[Equation 1]
Y TPC =-4.81776-0.015551X 1 +0.28967X 2 +0.21412X 3 +6.72730E-005X 1 X 2 +6.01865E-004X 1 X 3 -1.00677E-003X 2 X 3 -1.23645E-004X 1 2 - 2.01372 E-0.03X 2 2 -1.42821E-003X 3 2
[Equation 2]
Y TFC =-0.37372+9.55406E-003X 1 +9.20547E-003X 2 +2.05361E-003X 3 -9.72712E-005X 1 X 2 -5.20451E-005X 1 X 3 +5.37565E-005X 2 X 3 -1.77861E -005X 1 2 -4.02178E-005X 2 2 -1.79762E-005X 3 2
[Equation 3]
Y DPPH =-16.21374-0.19557X 1 +0.64596X 2 +1.96052X 3 +5.50661E-004X 1 X 2 +2.93686E-003X 1 X 3 -3.62518E-003X 2 X 3 +4.25974E-004X 1 2 -2.87540 E-003X 2 2 -0.013343X 3 2
In Equations 1 to 3, Y TPC is the predicted value of the total polyphenol content (mg GAE / g DM), Y TFC is the predicted value of the total flavonoid content (mg QE / g DM), Y DPPH is the predicted value of the DPPH radical scavenging ability ( %), X 1 is the extraction time, X 2 is the extraction temperature, and X 3 is the concentration of the extraction solvent.
상기 홍화씨 초음파 추출물은 홍화씨와 80 부피%의 에탄올 수용액을 60 내지 80 ℃의 추출온도 하에서 20 내지 50 kHz의 진동수 및 50 내지 700 W 파워의 초음파기로 45분 동안 처리되어 수득된 것을 특징으로 하는 피부암의 예방 또는 치료용 약학 조성물.Contains safflower seed ultrasonic extract as an active ingredient,
The ultrasonic extract of safflower seeds is obtained by treating safflower seeds and 80% by volume of an aqueous ethanol solution in an extraction temperature of 60 to 80 ° C. with an ultrasonicator of a frequency of 20 to 50 kHz and a power of 50 to 700 W for 45 minutes. A pharmaceutical composition for prophylaxis or treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200109017A KR102380115B1 (en) | 2020-08-28 | 2020-08-28 | Compositions containing safflower seed extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200109017A KR102380115B1 (en) | 2020-08-28 | 2020-08-28 | Compositions containing safflower seed extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220028259A KR20220028259A (en) | 2022-03-08 |
KR102380115B1 true KR102380115B1 (en) | 2022-03-30 |
Family
ID=80812587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200109017A KR102380115B1 (en) | 2020-08-28 | 2020-08-28 | Compositions containing safflower seed extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102380115B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240055323A (en) | 2022-10-20 | 2024-04-29 | 주식회사 팜스킨 | Cosmetic composition for anti-oxidation and blue light interception comprising ultrasonicating extract or fraction of Curcuma Longa |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100670237B1 (en) * | 2003-11-13 | 2007-01-17 | 주식회사 사임당화장품 | Cosmetic composition containing Safflower Seed Extract and extraction method of cosmetic effective composition from Safflower Seed |
KR20180066312A (en) * | 2016-12-07 | 2018-06-19 | 주식회사 지원바이오 | Method for optimal extraction of Camellia sinensis and Artemisia argyi mixture using response surface methodology |
KR20190006910A (en) * | 2017-07-11 | 2019-01-21 | 주식회사 톤28 | Blue light blocking cosmetic composition |
KR102141575B1 (en) | 2017-12-22 | 2020-08-05 | 한국과학기술원 | Cosmestic composition for blocking ultraviolet lays and blue light using electron beam irradiation and preparation method thereof |
KR20200089040A (en) | 2019-01-16 | 2020-07-24 | 충북대학교 산학협력단 | Composition for preventing, improving or treating cancer comprising Abeliophyllum distichum extract as effective component |
-
2020
- 2020-08-28 KR KR1020200109017A patent/KR102380115B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
AI-JUN HU 외 5명. KINETIC MODEL AND TECHNOLOGY OF ULTRASOUND EXTRACTION OF SAFFLOWER SEED OIL. Journal of Food Process Engineering, 35 (2012) 278-294 |
Eun Hee Jeong 외 3명. Safflower Seed Oil and Its Active Compound Acacetin Inhibit UVB-Induced Skin Photoaging. J. Microbiol. Biotechnol. 2020. 30(10): 1567-1573 |
Also Published As
Publication number | Publication date |
---|---|
KR20220028259A (en) | 2022-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102132833B1 (en) | Composition for anti-inflammation, or skin whitening | |
EP2937091B1 (en) | An extract of maqui berry for use in the treatment of dry eye | |
JP2008088123A (en) | Skin-beautifying composition | |
US20210060104A1 (en) | Antioxidant composition comprising sargassum serratifolium extract or fraction thereof as active ingredient | |
TW200528124A (en) | Active oxygen eliminator derived from natural substance and use thereof | |
KR101973639B1 (en) | Composition for anti oxidation containing extract of soybean leaf | |
KR102161179B1 (en) | Antioxidative composition comprising extract of red tea stem | |
JP2008074816A (en) | In vivo antioxidant | |
KR102380115B1 (en) | Compositions containing safflower seed extract | |
KR101816401B1 (en) | Composition for Anti-oxidation Containing Purified Fraction of Ginseng berry Extract | |
KR101004361B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
KR20120054946A (en) | Glucosinolate compound from broccoli and composition having antioxidant and antimicrobial activity comprising the same | |
KR102399204B1 (en) | Compositions containing black garlic extract | |
KR102358319B1 (en) | Sunscreen cosmetic composition comprising chestnut inner skin extract | |
KR101963841B1 (en) | Antioxidant composition comprising polyamine compounds isolated from Quercus Mongolica pollen extracts | |
KR102032830B1 (en) | Fuctional food improving skin condition comprising rice bran extract | |
JP2020189816A (en) | Vitamin C derivative composition | |
KR102579105B1 (en) | Compositions for skin whitening, UV protection, and anti skin cancer through enzymatic conversion of Luffa aegyptiaca extracts using probioticst | |
KR101440483B1 (en) | Composition for antiaging comprising extract or fraction of Ardisia tinctoria Pit. as an active ingredient | |
KR101989067B1 (en) | Composition Containing Coumestrin | |
KR100813638B1 (en) | Composition composition comprising apigenine | |
KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
KR20120044583A (en) | Method for boosting antioxidant activity in aloe extract using irradiation | |
KR101894433B1 (en) | Composition for skin whitening comprising tofu sunmul | |
KR101940055B1 (en) | Composition for skin moisturizing containing extract of soybean leaf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right |